Current status of oxaliplatin in colorectal cancer

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 6, 2003, Pages 78-87

  O'Dwyer, Peter J ^a   Johnson, Steven W ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXANE DERIVATIVE; DIAMINOCYCLOHEXANE; FLUOROURACIL; IRINOTECAN; LIGAND; OXALIPLATIN; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; LARYNX SPASM; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 0038176024     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)70028-1     Document Type: Article

References (55)

1. Connors TA, Jones M, Ross WC, et al: New platinum complexes with anti-tumor activity. Chem Biol Interact 5:415-424, 1972
2. Burchenal JH, Irani G, Kem K, et al: 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res 74:146-155, 1980
3. Schilder RJ, LaCreta FP, Perez RP, et al: Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 54:709-717, 1994
4. Kidani Y, Inagaki K: Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem 21:1315-1318, 1978
5. Noji M, Okamoto K, Kidani Y, et al: Relation of conformation to antitumor activity of platinum (II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl) cyclohexylamine isomers against leukemia P388. J Med Chem 24:508-515, 1981
6. Mathe G, Kidani Y, Triana K, et al: A phase I trial of trans-1-diaminacyclohexane oxalato-platinum (1-OHP). Biomed Pharmacother 40:372-376, 1986
7. Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303, 1990
8. O'Dwyer PJ, Stevenson JP, Haller DG, et al: Current status of the active platinum derivative oxaliplatin. Prin Pract Oncol Updates 15:1-16, 2001
9. Mauldin SK, Plescia M, Richard FA, et al: Displacement of the bidentate malonate ligand from (d,1-trans-1,2-diaminocyclohexane)malonatoplatinum(II) by physiologically important compounds in vitro. Biochem Pharmacol 37:3321-3333, 1988
10. Schmidt W, Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805, 1993
11. Scheeff ED, Howell SB: Computer modeling of the primary cisplatin and oxaliplatin DNA adducts and relevance to mismatch repair recognition. Proc Am Assoc Cancer Res 39:A1082, 1998 (abstr)
12. Fink D, Howell SB: How does cisplatin kill cells, in Kelland LR, Farrell NP (eds): Platinum-Based Drugs in Cancer Therapy. Totowa, NJ, Humana Press, 2000, pp 149-167
13. Chaney SG, Vaisman A: DNA adduct tolerance and bypass, in Kelland LR, Farrell NP (eds): Platinum-Based Drugs in Cancer Therapy. Totowa, NJ, Humana Press, 2000, pp 129-148
14. Zanke BW, Boudreau K, Rubie E, et al: The stress-activated protein kinase pathway mediates cell death following injury by cis-platinum, UV irradiation or heat. Curr Biol 6:606-613, 1996
15. Sanchez-Perez I, Murguia JR, Perona R: Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533-540, 1998
16. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103:239-252, 2000
17. Potapova O, Basu S, Mercola D, et al: Protective role for c-Jun in the cellular response to DNA damage. J Biol Chem 267:28546-28553, 2001
18. Pan B, Yao KS, Monia BP, et al: Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): Evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 63:1699-1707, 2002
19. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ: Geldanamycin and its 17-allylamino-17-demethoxy analogue (17-AAG) antagonize the action of cisplatin in human colon adenocarcinoma cells. Cancer Res 2003 (in press)
20. Graham MA, Lockwood GF, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218, 2000
21. Extra JM, Marty M, Brienza S, et al: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22, 1998 (suppl 5)
22. Gamelin E, Bouil AL, Boisdron-Celle M, et al: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 3:891-899, 1997
23. Lokiec F, Wasserman E, Santoni J, et al: Pharmacokinetics (PK) of the irinotecan (CPT-11)/oxaliplatin (LOHP) combination: Preliminary data of an ongoing phase I trial. Proc Am Assoc Cancer Res 38:76, 1997 (abstr)
24. Fischel JL, Formento P, Ciccolini J, et al: Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 86:1162-1168, 2002
25. Brienza S, Vignoud J, Itzhaki M, et al: Oxaliplatin (LOHP): Global safety in 682 patients (pts). Proc Am Soc Clin Oncol 14:209, 1995 (abstr 513)
26. Gamelin E, Gamelin L, Delva R, et al: Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/ Mg+ chloride infusions: A retrospective study. Proc Am Soc Clin Oncol 21:157a, 2002 (abstr 624)
27. Gamelin E, Gamelin L, Bossi L, et al: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Semin Oncol 29:21-33, 2002 (suppl 15)
28. Caussanel JP, Levi F, Brienza S, et al: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82:1046-1050, 1990
29. Becouarn Y, Ychou M, Ducreux M, et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 16:2739-2744, 1998
30. Diaz-Rubio E, Sastre J, Zaniboni A, et al: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 9:105-108, 1998
31. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95-98, 1996
32. Levi F, Perpoint B, Garufi C, et al: Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 9:1280-1284, 1993
33. Levi F, Misset JL, Brienza S, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900, 1992
34. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14:2950-2958, 1996
35. Levi F, Dogliotti L, Perpoint B, et al: A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 16:266a, 1997 (abstr 945)
36. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
37. Gerard B, Bleiberg H, Van Daele D, et al: Oxaliplatin combined to 5-fluorouracil and folinic acid: An effective therapy in patients with advanced colorectal cancer. Anticancer Drugs 9:301-305, 1998
38. Buechele T, Schoeber C, Kroening H, et al: Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU/FA in patients (PTS) with advanced colorectal cancer (CRC): A preliminary report. Proc Am Soc Clin Oncol 17:287a, 1998 (abstr 1106)
39. Andre T, Bensmaine MA, Louvet C, et al: Multicenter phase II trial of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568, 1999
40. Maindrault-Goebel F, Louvet C, Andre T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35:1338-1342, 1999
41. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 11:1477-1483, 2000
42. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
43. Scheithauer W, Kornek GV, Raderer M, et al: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 17:902-906, 1999
44. Rougier P, Lepille D, Douillard J, et al: Final results of a randomised phase II study of three combinations: CPT-11 + LV5FU2, LOHP + LV5FU2, and CPT-11 + LOHP in 5-FU resistant advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 20:142a, 2001 (abstr 566)
45. Scheithauer W, Komek GV, Ulrich-Pur H, et al: Irinotecan (CPT-11) plus oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A randomized phase II study. Proc Am Soc Clin Oncol 20:135a, 2001 (abstr 538)
46. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
47. Levi FA, Zidani R, Vannetzel JM, et al: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 86: 1608-1617, 1994
48. Levi F, Zidani R, Misset JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686, 1997
49. Giachetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as the first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
50. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
51. Grothey A, Deschler B, Kroening H, et al: Bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC). Results of a phase III study. Proc Am Soc Clin Oncol 20:125a, 2001 (abstr 496)
52. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:129a, 2002 (abstr 512)
53. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
54. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 20:124a, 2001 (abstr 494)
55. O'Dwyer PJ, Manola J, Valone FH, et al: Fluorouracil modulation in colorectal cancer: Lack of improvement with PALA or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusional schedule. An ECOG/CALGB study. J Clin Oncol 19:2413-2421, 2001